SOM Biotech announces poster presentation on the repurposing of Eravacycline for the treatment of SARS-CoV-2

posted on October 19, 2020

SOM Biotech announces today that it will present in silico and in vitro results regarding Eravacycline for the treatment of SARS-CoV-2 during a virtual poster presentation at the IDWeek 2020.

The poster is entitled “Repurposing of Eravacycline for the Treatment of SARS-CoV-2 Infections”. It outlines pre-clinical data demonstrating that Eravacycline is a potent inhibitor of the SARS-CoV-2 3CL protease.

Eravacycline was identified using an AI-based screening technology (SOMAIPRO), that analyzed a database of clinically tested compounds in search of inhibitors of SARS-CoV-2 3CL protease, a viral protein essential for coronavirus infection and replication in host cells.

Covalent docking calculations demonstrated that Eravacycline establishes a covalent bond with Cys145 in the catalytic domain of the SARS-CoV-2 3CL protease. In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.

The studies also showed that Eravacycline inhibits the 3CL proteases of other related coronaviruses, such as SARS-CoV and MERS-CoV. Thus, the data suggest that the drug could be repositioned for the treatment of beta-coronaviruses infections.

“It is a pleasure to share our in vitro findings on Eravacycline for the treatment of SARS-CoV-2 and to target the hospitalized patients by the virus. The drug accumulates in the lung and has anti-inflammatory and antibacterial activity. Therefore, it may play an important role in treating COVID-19 infections, additionally to its inhibitory capacity for virus replication. We are planning a Phase 2 clinical trial to prove the efficacy of Eravacycline in hospitalized COVID-19 patients”, says Raul Insa, CEO of SOM Biotech.

Presentation details as follows:

Session Category: Posters

Session Title: COVID-19 treatment

Presenter: Núria Reig

Poster Board Number: 560 – Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections

Abstract Number: 910853

Location: webpage of congress.

IDWeek2020. SOM Biotech. Treatment of SARS-CoV-2